The most popular brand in the world, the Medtronic, has its sights set on a lot of things.
So much so that the pharmaceutical giant recently filed for Chapter 11 bankruptcy protection in the U.S. It is not a surprising move, given that Medtronics is the world’s most popular generic medication and that its competitors include several of the most popular brands on the market.
And it’s not hard to see why: The generic drug industry is a major driver of economic growth and a key driver of innovation.
But it is also a powerful political force.
According to a new report by the Center for Effective Government at Harvard University, generic drugmakers are among the biggest spenders in American politics.
And they spend significantly more than their competitors.
“It’s not just that pharmaceutical companies are the biggest spender in American elections,” said Brian Blanco, a senior fellow at the center and the author of the report.
“That’s not a bad thing.
It’s a fact.
But they’re also spending far more than other industries in a lot more ways.”
Here are the top generic drug spending spenders in American history: The Medtrolax brand of the drug used to treat depression, anxiety and other mental illnesses is the most frequently purchased brand.
It has made a total of $14.8 billion in sales since 2003.
It accounted for more than half of all the sales of the MedTrolax, and it’s now the second most valuable generic drug after Pfizer.
This brand was once the darling of the pharmaceutical industry, but over the past decade, it has been overtaken by generic drug makers like Pfizer and other generic drug manufacturers.
In 2010, for example, it surpassed Pfizer’s sales of $7.6 billion for the year, thanks to a surge in the sales it was able to capture by selling the drug directly to patients through a network of clinics, which was able, in part, because of the availability of generic drugs.
Over the last decade, the generic drug market has grown at a rate of 25 percent a year.
It now accounts for more market share than any other market segment, with sales up 27 percent since 2003, according to a study by the nonpartisan Congressional Budget Office.
Meanwhile, Pfizer has taken a more prominent role in the drug market over the last few years.
In 2012, the company bought rival company EpiPen, which makes the epinephrine injector used by people with serious health problems.
It sold nearly $1 billion worth of the EpiPens, which were made by rival company Eli Lilly, in a deal valued at $8.7 billion.
Since 2012, Eli Lilly has been the largest purchaser of generic drug sales in the country, and its sales rose by 33 percent in the same period.
And the price of EpiPs is so low that it’s cheaper to buy a generic drug today than it was when the drug first hit the market in 2001.
Eli Lilly’s stock is up nearly 50 percent this year and is up more than 30 percent over the year.
Its market capitalization is about $1.2 trillion.
That makes it one of the biggest purchasers of generic medicine in the United States, and the company has also spent billions on lobbying.
Eli, for its part, has made some aggressive efforts to influence policy around the generic drugs issue.
In 2017, the drug company wrote letters to Congress, including to Sens.
Dianne Feinstein (D-Calif.) and Bernie Sanders (I-Vt.), calling on Congress to pass legislation that would require the FDA to allow generic drugs to be available over the counter.
In response, Feinstein and Sanders both introduced legislation that includes some provisions for allowing generic drugs over the counters.
But this is not enough to stop drugmakers from buying up generic drugs without approval.
In addition to buying up a significant portion of the generic market, generic pharmaceutical companies also spend significantly less on political advertising than their more expensive competitors.
This year, generic drugs accounted for just 7 percent of the advertising budgets spent by pharmaceutical companies, according the Center on Media and Democracy, which monitors election campaigns.
And a recent report by Transparency International found that while the amount of campaign money spent by generic drugs companies has risen, they have also dropped from an average of nearly 10 percent of their spending to just over 4 percent.
This means that generic drug companies have spent nearly as much money on advertising as other brands, and they’ve been spending more money on political ads.
A company that makes a generic version of a drug that is sold over the Internet could, for instance, spend $100,000 in advertising a few months after the election, compared with $30,000 for an opponent of the same drug.
In fact, a pharmaceutical company that bought a generic generic version in 2014, called Epidiolex, has spent nearly $100 million on political advertisements in just the last six months of 2017, according a New York Times analysis of company